Vascular Biogenics Ltd. (VBLT)

NASDAQ: VBLT · IEX Real-Time Price · USD
0.219
-0.012 (-5.00%)
Jun 2, 2023, 4:00 PM EDT - Market closed
-5%
Market Cap 15.40M
Revenue (ttm) 545,000
Net Income (ttm) -24.52M
Shares Out 70.50M
EPS (ttm) 0.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 916,469
Open 0.225
Previous Close 0.230
Day's Range 0.213 - 0.230
52-Week Range 0.101 - 2.200
Beta 0.68
Analysts Hold
Price Target 5.50 (+2,417.16%)
Earnings Date May 26, 2023

About VBLT

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 1, 2014
Employees 7
Stock Exchange NASDAQ
Ticker Symbol VBLT
Full Company Profile

Financial Performance

In 2022, VBLT's revenue was $658,000, a decrease of -14.32% compared to the previous year's $768,000. Losses were -$32.30 million, 7.97% more than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for VBLT stock is "Hold." The 12-month stock price forecast is $5.5, which is an increase of 2,417.16% from the latest price.

Price Target
$5.5
(2,417.16% upside)
Analyst Consensus: Hold
Stock Forecasts

News

VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction in Q3 2023, subject to SEC review and shareholder approvals Recently filed S-4 registration...

2 weeks ago - GlobeNewsWire

VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a cor...

2 months ago - GlobeNewsWire

VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash

MODIIN, Israel and NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in Mod...

3 months ago - GlobeNewsWire
}

Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership

REHOVOT, Israel--(BUSINESS WIRE)-- #COP26--Aleph Farms, the first company to grow cultivated steaks directly from non-modified cow cells, today announced that it has acquired a manufacturing facility ...

3 months ago - Business Wire

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vascular Biogenics Ltd. - VBLT

NEW YORK , Feb. 27, 2023 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm r...

3 months ago - PRNewsWire

VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Vascular Bioge...

3 months ago - Business Wire

VBLT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Vascular Biogenics Ltd. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Vascular Biogenics Ltd. (NASDAQ: VBLT) and Notable Labs, Inc. is fair to Vascular share...

3 months ago - Business Wire

VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable's proprietary Predictive Precision Med...

3 months ago - GlobeNewsWire
}

VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash

MODIIN, Israel and NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced today ...

3 months ago - GlobeNewsWire

VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Continued progress on previously announced strategic process to maximize shareholder value Continued progress on previously announced strategic process to maximize shareholder value

7 months ago - GlobeNewsWire

VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

TEL AVIV, Israel and NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today...

9 months ago - GlobeNewsWire

VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options

Exploring strategic options to maximize shareholder value; engaged Chardan as financial advisor Exploring strategic options to maximize shareholder value; engaged Chardan as financial advisor

10 months ago - GlobeNewsWire

VBL Therapeutics Announces Workforce Reduction

TEL AVIV, Israel and NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, toda...

10 months ago - GlobeNewsWire
}

Why Vascular Biogenics Stock Is Plunging

Vascular Biogenics Ltd (NASDAQ: VBLT) shares are falling Wednesday after the company announced that the data from its Phase 3 OVAL trial of ofra-vec in platinum-resistant ovarian cancer did not meet t...

11 months ago - Benzinga

VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer

- Trial Did Not Meet Statistical Significance on Improvement in Primary Endpoints of Progression Free Survival (PFS) or Overall Survival (OS) - - Trial Did Not Meet Statistical Significance on Improve...

11 months ago - GlobeNewsWire

VBL Therapeutics to Participate in the Jefferies Healthcare Conference

TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-...

1 year ago - GlobeNewsWire

VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023

1 year ago - GlobeNewsWire

VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17

TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for diffi...

1 year ago - GlobeNewsWire

VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May

TEL AVIV, Israel and NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for diffi...

1 year ago - GlobeNewsWire

VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TEL AVIV, Israel and NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-t...

1 year ago - GlobeNewsWire

VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer

TEL AVIV, Israel and NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for dif...

1 year ago - GlobeNewsWire

VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer

Three leading experts in gynecological oncology will discuss treatment landscape and unmet needs in ovarian cancer

1 year ago - GlobeNewsWire

VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update

TEL AVIV, Israel and NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics f...

1 year ago - GlobeNewsWire

UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23

TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for dif...

1 year ago - GlobeNewsWire

VLB Therapeutics to Report Year-End 2021 Financial Results on March 23

TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for dif...

1 year ago - GlobeNewsWire